View ValuationPharmena 将来の成長Future 基準チェック /06現在、 Pharmenaの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Personal Products 収益成長8.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 21Pharmena S.A., Annual General Meeting, Jun 25, 2026Pharmena S.A., Annual General Meeting, Jun 25, 2026, at 11:00 Central European Standard Time.New Risk • Mar 02New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: zł35.1m (US$9.67m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł3.3m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Revenue is less than US$1m (zł1.6m revenue, or US$435k). Market cap is less than US$10m (zł35.1m market cap, or US$9.67m).Reported Earnings • Feb 26Full year 2025 earnings released: zł0.25 loss per share (vs zł0.11 loss in FY 2024)Full year 2025 results: zł0.25 loss per share (further deteriorated from zł0.11 loss in FY 2024). Revenue: zł1.58m (up 488% from FY 2024). Net loss: zł2.77m (loss widened 119% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 23% per year whereas the company’s share price has fallen by 18% per year.New Risk • Jan 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł2.9m free cash flow). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Revenue is less than US$1m (zł1.3m revenue, or US$354k). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (zł36.8m market cap, or US$10.2m).Reported Earnings • Dec 03Third quarter 2025 earnings released: zł0.062 loss per share (vs zł0.043 loss in 3Q 2024)Third quarter 2025 results: zł0.062 loss per share (further deteriorated from zł0.043 loss in 3Q 2024). Revenue: zł407.0k (up zł385.0k from 3Q 2024). Net loss: zł690.0k (loss widened 45% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.お知らせ • Aug 20Pharmena S.A. to Report First Half, 2025 Results on Aug 29, 2025Pharmena S.A. announced that they will report first half, 2025 results on Aug 29, 2025New Risk • Jul 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł2.7m free cash flow). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Revenue is less than US$1m (zł268k revenue, or US$74k). Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Market cap is less than US$100m (zł39.0m market cap, or US$10.8m).New Risk • Jun 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: zł36.0m (US$9.72m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł2.7m free cash flow). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Revenue is less than US$1m (zł268k revenue, or US$72k). Market cap is less than US$10m (zł36.0m market cap, or US$9.72m).お知らせ • May 23Pharmena S.A., Annual General Meeting, Jun 25, 2025Pharmena S.A., Annual General Meeting, Jun 25, 2025.New Risk • May 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł2.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł2.7m free cash flow). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Revenue is less than US$1m (zł268k revenue, or US$70k). Minor Risk Market cap is less than US$100m (zł44.4m market cap, or US$11.6m).New Risk • Dec 23New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: zł41.0m (US$10.00m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Revenue is less than US$1m (zł308k revenue, or US$75k). Market cap is less than US$10m (zł41.0m market cap, or US$10.00m).Reported Earnings • Dec 02Third quarter 2024 earnings released: zł0.043 loss per share (vs zł2.71 profit in 3Q 2023)Third quarter 2024 results: zł0.043 loss per share (down from zł2.71 profit in 3Q 2023). Net loss: zł475.0k (down 102% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 29Second quarter 2024 earnings released: zł0.081 loss per share (vs zł0.051 loss in 2Q 2023)Second quarter 2024 results: zł0.081 loss per share (further deteriorated from zł0.051 loss in 2Q 2023). Net loss: zł904.0k (loss widened 59% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.分析記事 • Jun 04We Think Pharmena's (WSE:PHR) Solid Earnings Are UnderstatedPharmena S.A.'s ( WSE:PHR ) recent earnings report didn't offer any surprises, with the shares unchanged over the last...Reported Earnings • May 27First quarter 2024 earnings released: EPS: zł0.021 (vs zł0.014 loss in 1Q 2023)First quarter 2024 results: EPS: zł0.021 (up from zł0.014 loss in 1Q 2023). Net income: zł235.0k (up zł390.0k from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Apr 11Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to zł7.24, the stock trades at a trailing P/E ratio of 3x. Average trailing P/E is 25x in the Personal Products industry in Europe. Total loss to shareholders of 26% over the past three years.Upcoming Dividend • Apr 02Upcoming dividend of zł0.85 per shareEligible shareholders must have bought the stock before 09 April 2024. Payment date: 24 April 2024. Trailing yield: 10%. Within top quartile of Polish dividend payers (7.6%). Higher than average of industry peers (2.1%).New Risk • Mar 17New minor risk - Dividend sustainabilityThe company has a short dividend paying track record. Less than a year of continuous dividend payments. Dividend yield: 11% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Short dividend paying track record (less than a year of continuous dividend payments). Share price has been volatile over the past 3 months (9.8% average weekly change). Revenue is less than US$5m (zł19m revenue, or US$4.8m). Market cap is less than US$100m (zł88.7m market cap, or US$22.4m).お知らせ • Mar 09Pharmena S.A., Annual General Meeting, Apr 03, 2024Pharmena S.A., Annual General Meeting, Apr 03, 2024, at 11:00 Central European Standard Time.New Risk • Feb 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.5% average weekly change). Minor Risks Revenue is less than US$5m (zł19m revenue, or US$4.8m). Market cap is less than US$100m (zł82.2m market cap, or US$20.7m).Valuation Update With 7 Day Price Move • Feb 20Investor sentiment improves as stock rises 18%After last week's 18% share price gain to zł8.10, the stock trades at a trailing P/E ratio of 3.2x. Average trailing P/E is 23x in the Personal Products industry in Europe. Total loss to shareholders of 28% over the past three years.お知らせ • Jan 24+ 2 more updatesPharmena S.A. to Report Q3, 2024 Results on Nov 27, 2024Pharmena S.A. announced that they will report Q3, 2024 results on Nov 27, 2024Valuation Update With 7 Day Price Move • Jan 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to zł7.70, the stock trades at a trailing P/E ratio of 3x. Average trailing P/E is 27x in the Personal Products industry in Poland. Total loss to shareholders of 18% over the past three years.Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improves as stock rises 20%After last week's 20% share price gain to zł7.10, the stock trades at a trailing P/E ratio of 2.8x. Average trailing P/E is 26x in the Personal Products industry in Poland. Total loss to shareholders of 21% over the past three years.分析記事 • Dec 04Pharmena's (WSE:PHR) Solid Earnings Are Supported By Other Strong FactorsPharmena S.A.'s ( WSE:PHR ) strong earnings report was rewarded with a positive stock price move. We have done some...Reported Earnings • Nov 29Third quarter 2023 earnings released: EPS: zł2.70 (vs zł0.01 loss in 3Q 2022)Third quarter 2023 results: EPS: zł2.70 (up from zł0.01 loss in 3Q 2022). Net income: zł30.1m (up zł30.2m from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.お知らせ • May 16Pharmena S.A., Annual General Meeting, Jun 13, 2023Pharmena S.A., Annual General Meeting, Jun 13, 2023, at 11:00 Central European Standard Time.お知らせ • Jan 20+ 3 more updatesPharmena S.A. to Report Q1, 2023 Results on May 26, 2023Pharmena S.A. announced that they will report Q1, 2023 results on May 26, 2023Reported Earnings • Nov 27Third quarter 2022 earnings released: zł0.01 loss per share (vs zł0.053 loss in 3Q 2021)Third quarter 2022 results: zł0.01 loss per share (improved from zł0.053 loss in 3Q 2021). Revenue: zł4.56m (up 14% from 3Q 2021). Net loss: zł110.0k (loss narrowed 82% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 28Second quarter 2022 earnings released: zł0.041 loss per share (vs zł0.17 loss in 2Q 2021)Second quarter 2022 results: zł0.041 loss per share (up from zł0.17 loss in 2Q 2021). Revenue: zł4.69m (up 35% from 2Q 2021). Net loss: zł462.0k (loss narrowed 76% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Reported Earnings • Jun 01First quarter 2022 earnings released: zł0.015 loss per share (vs zł0.052 loss in 1Q 2021)First quarter 2022 results: zł0.015 loss per share (up from zł0.052 loss in 1Q 2021). Revenue: zł3.63m (up 10.0% from 1Q 2021). Net loss: zł171.0k (loss narrowed 70% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.お知らせ • May 31Pharmena S.A., Annual General Meeting, Jun 28, 2022Pharmena S.A., Annual General Meeting, Jun 28, 2022, at 11:00 Central European Standard Time.お知らせ • Feb 01+ 3 more updatesPharmena S.A. to Report Q3, 2022 Results on Nov 25, 2022Pharmena S.A. announced that they will report Q3, 2022 results on Nov 25, 2022Reported Earnings • Nov 28Third quarter 2021 earnings: EPS in line with expectations, revenues disappointThird quarter 2021 results: zł0.053 loss per share (up from zł0.068 loss in 3Q 2020). Revenue: zł4.00m (up 33% from 3Q 2020). Net loss: zł595.0k (loss narrowed 20% from 3Q 2020). Revenue missed analyst estimates by 2.5%. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.Reported Earnings • Jun 03First quarter 2021 earnings released: zł0.052 loss per share (vs zł0.069 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: zł3.30m (up 30% from 1Q 2020). Net loss: zł568.0k (loss narrowed 25% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.Reported Earnings • Apr 15Full year 2020 earnings released: zł0.63 loss per share (vs zł0.94 loss in FY 2019)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: zł9.93m (down 11% from FY 2019). Net loss: zł6.89m (loss narrowed 27% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.お知らせ • Jan 23+ 3 more updatesPharmena S.A. to Report First Half, 2021 Results on Aug 27, 2021Pharmena S.A. announced that they will report first half, 2021 results on Aug 27, 2021Is New 90 Day High Low • Dec 18New 90-day low: zł8.94The company is down 15% from its price of zł10.50 on 18 September 2020. The Polish market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is down 31% over the same period.Reported Earnings • Nov 28Third quarter 2020 earnings released: zł0.068 loss per shareThe company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were weaker. Third quarter 2020 results: Revenue: zł3.01m (down 11% from 3Q 2019). Net loss: zł746.0k (loss narrowed 35% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Oct 15New 90-day low: zł9.20The company is down 32% from its price of zł13.45 on 17 July 2020. The Polish market is down 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 36% over the same period.お知らせ • Oct 11Pharmena S.A. announced that it expects to receive PLN 1.5 million in fundingPharmena S.A. (WSE:PHR) announced a private placement of series F shares at not more than PLN 13.1 per share for gross proceeds of PLN 1,500,000 on October 9, 2020. The transaction may include participation from Pelion SA. The company’s board of directors has approved the transaction. The transaction is subject approval of shareholders, which will held on November 5, 2020. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Pharmena は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測WSE:PHR - アナリストの将来予測と過去の財務データ ( )PLN Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20252-3-4-3N/A9/30/20251-2-3-3N/A6/30/20251-2-2-2N/A3/31/20251-2-2-1N/A12/31/20240-1-3-3N/A9/30/20240-1-3-3N/A6/30/2024029-15-15N/A3/31/20240293030N/A12/31/20230273333N/A9/30/20230263434N/A6/30/20230-74647N/A3/31/2023-3-633N/A12/31/20220-522N/A9/30/20225-511N/A6/30/20229-300N/A3/31/202216-4-1-1N/A12/31/202115-5-4-3N/A9/30/202113-7-5-4N/A6/30/202112-7-5-4N/A3/31/202111-7-5-5N/A12/31/202010-7-2-2N/A9/30/202010-6-3-2N/A6/30/202010-6-4-4N/A3/31/202010-10-10-9N/A12/31/201911-9-13-13N/A9/30/201912-8N/A-10N/A6/30/201912-7N/A-7N/A3/31/201913-2N/A-1N/A12/31/2018130N/A4N/A9/30/2018130N/A2N/A6/30/201813-1N/A1N/A3/31/201814-1N/A0N/A12/31/201712-2N/A1N/A9/30/201714-2N/A0N/A6/30/201716-2N/A1N/A3/31/201716-1N/A-1N/A12/31/201616-2N/A-1N/A9/30/201616-4N/A-4N/A6/30/201616-4N/A-4N/A3/31/201616-4N/A-3N/A12/31/201517-4N/A-4N/A9/30/201517-3N/A-2N/A6/30/201515-3N/A-3N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PHRの予測収益成長が 貯蓄率 ( 5.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: PHRの収益がPolish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: PHRの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: PHRの収益がPolish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: PHRの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PHRの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHousehold 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 21:04終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pharmena S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Adrian KowollikDr. Kalliwoda ResearchAdrian KowollikEast Value Research GmbH
お知らせ • May 21Pharmena S.A., Annual General Meeting, Jun 25, 2026Pharmena S.A., Annual General Meeting, Jun 25, 2026, at 11:00 Central European Standard Time.
New Risk • Mar 02New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: zł35.1m (US$9.67m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł3.3m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Revenue is less than US$1m (zł1.6m revenue, or US$435k). Market cap is less than US$10m (zł35.1m market cap, or US$9.67m).
Reported Earnings • Feb 26Full year 2025 earnings released: zł0.25 loss per share (vs zł0.11 loss in FY 2024)Full year 2025 results: zł0.25 loss per share (further deteriorated from zł0.11 loss in FY 2024). Revenue: zł1.58m (up 488% from FY 2024). Net loss: zł2.77m (loss widened 119% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 23% per year whereas the company’s share price has fallen by 18% per year.
New Risk • Jan 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł2.9m free cash flow). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Revenue is less than US$1m (zł1.3m revenue, or US$354k). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (zł36.8m market cap, or US$10.2m).
Reported Earnings • Dec 03Third quarter 2025 earnings released: zł0.062 loss per share (vs zł0.043 loss in 3Q 2024)Third quarter 2025 results: zł0.062 loss per share (further deteriorated from zł0.043 loss in 3Q 2024). Revenue: zł407.0k (up zł385.0k from 3Q 2024). Net loss: zł690.0k (loss widened 45% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
お知らせ • Aug 20Pharmena S.A. to Report First Half, 2025 Results on Aug 29, 2025Pharmena S.A. announced that they will report first half, 2025 results on Aug 29, 2025
New Risk • Jul 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł2.7m free cash flow). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Revenue is less than US$1m (zł268k revenue, or US$74k). Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Market cap is less than US$100m (zł39.0m market cap, or US$10.8m).
New Risk • Jun 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: zł36.0m (US$9.72m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł2.7m free cash flow). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Revenue is less than US$1m (zł268k revenue, or US$72k). Market cap is less than US$10m (zł36.0m market cap, or US$9.72m).
お知らせ • May 23Pharmena S.A., Annual General Meeting, Jun 25, 2025Pharmena S.A., Annual General Meeting, Jun 25, 2025.
New Risk • May 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł2.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł2.7m free cash flow). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Revenue is less than US$1m (zł268k revenue, or US$70k). Minor Risk Market cap is less than US$100m (zł44.4m market cap, or US$11.6m).
New Risk • Dec 23New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: zł41.0m (US$10.00m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Revenue is less than US$1m (zł308k revenue, or US$75k). Market cap is less than US$10m (zł41.0m market cap, or US$10.00m).
Reported Earnings • Dec 02Third quarter 2024 earnings released: zł0.043 loss per share (vs zł2.71 profit in 3Q 2023)Third quarter 2024 results: zł0.043 loss per share (down from zł2.71 profit in 3Q 2023). Net loss: zł475.0k (down 102% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 29Second quarter 2024 earnings released: zł0.081 loss per share (vs zł0.051 loss in 2Q 2023)Second quarter 2024 results: zł0.081 loss per share (further deteriorated from zł0.051 loss in 2Q 2023). Net loss: zł904.0k (loss widened 59% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
分析記事 • Jun 04We Think Pharmena's (WSE:PHR) Solid Earnings Are UnderstatedPharmena S.A.'s ( WSE:PHR ) recent earnings report didn't offer any surprises, with the shares unchanged over the last...
Reported Earnings • May 27First quarter 2024 earnings released: EPS: zł0.021 (vs zł0.014 loss in 1Q 2023)First quarter 2024 results: EPS: zł0.021 (up from zł0.014 loss in 1Q 2023). Net income: zł235.0k (up zł390.0k from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Apr 11Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to zł7.24, the stock trades at a trailing P/E ratio of 3x. Average trailing P/E is 25x in the Personal Products industry in Europe. Total loss to shareholders of 26% over the past three years.
Upcoming Dividend • Apr 02Upcoming dividend of zł0.85 per shareEligible shareholders must have bought the stock before 09 April 2024. Payment date: 24 April 2024. Trailing yield: 10%. Within top quartile of Polish dividend payers (7.6%). Higher than average of industry peers (2.1%).
New Risk • Mar 17New minor risk - Dividend sustainabilityThe company has a short dividend paying track record. Less than a year of continuous dividend payments. Dividend yield: 11% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Short dividend paying track record (less than a year of continuous dividend payments). Share price has been volatile over the past 3 months (9.8% average weekly change). Revenue is less than US$5m (zł19m revenue, or US$4.8m). Market cap is less than US$100m (zł88.7m market cap, or US$22.4m).
お知らせ • Mar 09Pharmena S.A., Annual General Meeting, Apr 03, 2024Pharmena S.A., Annual General Meeting, Apr 03, 2024, at 11:00 Central European Standard Time.
New Risk • Feb 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.5% average weekly change). Minor Risks Revenue is less than US$5m (zł19m revenue, or US$4.8m). Market cap is less than US$100m (zł82.2m market cap, or US$20.7m).
Valuation Update With 7 Day Price Move • Feb 20Investor sentiment improves as stock rises 18%After last week's 18% share price gain to zł8.10, the stock trades at a trailing P/E ratio of 3.2x. Average trailing P/E is 23x in the Personal Products industry in Europe. Total loss to shareholders of 28% over the past three years.
お知らせ • Jan 24+ 2 more updatesPharmena S.A. to Report Q3, 2024 Results on Nov 27, 2024Pharmena S.A. announced that they will report Q3, 2024 results on Nov 27, 2024
Valuation Update With 7 Day Price Move • Jan 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to zł7.70, the stock trades at a trailing P/E ratio of 3x. Average trailing P/E is 27x in the Personal Products industry in Poland. Total loss to shareholders of 18% over the past three years.
Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improves as stock rises 20%After last week's 20% share price gain to zł7.10, the stock trades at a trailing P/E ratio of 2.8x. Average trailing P/E is 26x in the Personal Products industry in Poland. Total loss to shareholders of 21% over the past three years.
分析記事 • Dec 04Pharmena's (WSE:PHR) Solid Earnings Are Supported By Other Strong FactorsPharmena S.A.'s ( WSE:PHR ) strong earnings report was rewarded with a positive stock price move. We have done some...
Reported Earnings • Nov 29Third quarter 2023 earnings released: EPS: zł2.70 (vs zł0.01 loss in 3Q 2022)Third quarter 2023 results: EPS: zł2.70 (up from zł0.01 loss in 3Q 2022). Net income: zł30.1m (up zł30.2m from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
お知らせ • May 16Pharmena S.A., Annual General Meeting, Jun 13, 2023Pharmena S.A., Annual General Meeting, Jun 13, 2023, at 11:00 Central European Standard Time.
お知らせ • Jan 20+ 3 more updatesPharmena S.A. to Report Q1, 2023 Results on May 26, 2023Pharmena S.A. announced that they will report Q1, 2023 results on May 26, 2023
Reported Earnings • Nov 27Third quarter 2022 earnings released: zł0.01 loss per share (vs zł0.053 loss in 3Q 2021)Third quarter 2022 results: zł0.01 loss per share (improved from zł0.053 loss in 3Q 2021). Revenue: zł4.56m (up 14% from 3Q 2021). Net loss: zł110.0k (loss narrowed 82% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 28Second quarter 2022 earnings released: zł0.041 loss per share (vs zł0.17 loss in 2Q 2021)Second quarter 2022 results: zł0.041 loss per share (up from zł0.17 loss in 2Q 2021). Revenue: zł4.69m (up 35% from 2Q 2021). Net loss: zł462.0k (loss narrowed 76% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Reported Earnings • Jun 01First quarter 2022 earnings released: zł0.015 loss per share (vs zł0.052 loss in 1Q 2021)First quarter 2022 results: zł0.015 loss per share (up from zł0.052 loss in 1Q 2021). Revenue: zł3.63m (up 10.0% from 1Q 2021). Net loss: zł171.0k (loss narrowed 70% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
お知らせ • May 31Pharmena S.A., Annual General Meeting, Jun 28, 2022Pharmena S.A., Annual General Meeting, Jun 28, 2022, at 11:00 Central European Standard Time.
お知らせ • Feb 01+ 3 more updatesPharmena S.A. to Report Q3, 2022 Results on Nov 25, 2022Pharmena S.A. announced that they will report Q3, 2022 results on Nov 25, 2022
Reported Earnings • Nov 28Third quarter 2021 earnings: EPS in line with expectations, revenues disappointThird quarter 2021 results: zł0.053 loss per share (up from zł0.068 loss in 3Q 2020). Revenue: zł4.00m (up 33% from 3Q 2020). Net loss: zł595.0k (loss narrowed 20% from 3Q 2020). Revenue missed analyst estimates by 2.5%. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
Reported Earnings • Jun 03First quarter 2021 earnings released: zł0.052 loss per share (vs zł0.069 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: zł3.30m (up 30% from 1Q 2020). Net loss: zł568.0k (loss narrowed 25% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.
Reported Earnings • Apr 15Full year 2020 earnings released: zł0.63 loss per share (vs zł0.94 loss in FY 2019)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: zł9.93m (down 11% from FY 2019). Net loss: zł6.89m (loss narrowed 27% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
お知らせ • Jan 23+ 3 more updatesPharmena S.A. to Report First Half, 2021 Results on Aug 27, 2021Pharmena S.A. announced that they will report first half, 2021 results on Aug 27, 2021
Is New 90 Day High Low • Dec 18New 90-day low: zł8.94The company is down 15% from its price of zł10.50 on 18 September 2020. The Polish market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is down 31% over the same period.
Reported Earnings • Nov 28Third quarter 2020 earnings released: zł0.068 loss per shareThe company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were weaker. Third quarter 2020 results: Revenue: zł3.01m (down 11% from 3Q 2019). Net loss: zł746.0k (loss narrowed 35% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Oct 15New 90-day low: zł9.20The company is down 32% from its price of zł13.45 on 17 July 2020. The Polish market is down 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 36% over the same period.
お知らせ • Oct 11Pharmena S.A. announced that it expects to receive PLN 1.5 million in fundingPharmena S.A. (WSE:PHR) announced a private placement of series F shares at not more than PLN 13.1 per share for gross proceeds of PLN 1,500,000 on October 9, 2020. The transaction may include participation from Pelion SA. The company’s board of directors has approved the transaction. The transaction is subject approval of shareholders, which will held on November 5, 2020.